

## ARIC Manuscript Proposal #2002

PC Reviewed: 9/11/12  
SC Reviewed: \_\_\_\_\_

Status: A  
Status: \_\_\_\_\_

Priority: 2  
Priority: \_\_\_\_\_

**1.a. Full Title:** Association of High-Sensitivity Cardiac Troponin T (hs-cTnT) with Cognitive Function: the Atherosclerosis Risk in Communities Study

**b. Abbreviated Title (Length 26 characters):** Troponin and Cognition

### 2. Writing Group:

Writing group members: Andrea L.C. Schneider, Andreea M. Rawlings, Richey Sharrett, Alvaro Alonso, Thomas Mosley, Ron Hoogeveen, Christie M. Ballantyne, Rebecca Gottesman, Elizabeth Selvin; others welcome

I, the first author, confirm that all the coauthors have given their approval for this manuscript proposal. ALCS & AR [please confirm with your initials electronically or in writing]

**Co-first authors:** Andrea L.C. Schneider & Andreea M. Rawlings

Address: Welch Center for Prevention, Epidemiology, and Clinical Research  
Johns Hopkins Bloomberg School of Public Health  
2024 E. Monument St., Suite 2-600  
Baltimore, MD 21287

Phone: 410 502 2509      Fax: 410 955 0476

E-mail: achris13@jhmi.edu, arawling@jhsph.edu

**ARIC author** to be contacted if there are questions about the manuscript and the first author does not respond or cannot be located (this must be an ARIC investigator).

Name: Elizabeth Selvin

Address: Department of Epidemiology  
Johns Hopkins Bloomberg School of Public Health  
Welch Center for Prevention, Epidemiology, and Clinical Research  
2024 E. Monument Street, Suite 2-600  
Baltimore, MD 21287

Phone: 410 614 3752      Fax: 410 955 0476

E-mail: lselvin@jhsph.edu

**3. Timeline:** Data is currently available; plan to submit as abstract to the American Heart Association-Epi/NPAM Conference and to submit for publication by March 2013.

#### **4. Rationale:**

Dementia affects approximately 14% of persons aged 70 or older in the United States (1) and this estimate is expected to triple by the year 2030 (2). Overt cardiovascular disease has been shown to be a major risk factor for dementia and cognitive impairment (3-5), however the association of subclinical cardiovascular disease with dementia and cognitive impairment is less well characterized.

Novel highly sensitivity assays for cardiac troponin can detect troponin levels approximately 10-times lower than standard cardiac troponin assays that are currently used in clinical practice to diagnose myocardial infarction (6). These novel highly sensitive assays are not yet approved for clinical use. Recent studies have shown that troponin levels measured using these new ultra highly sensitive assays can improve the prediction of cardiovascular disease and mortality in community-based populations without clinically evident cardiovascular disease (7, 8). Troponin is highly specific to the myocardium and minute levels of circulating troponin that can be detected by novel highly sensitive assays are thought to be a novel marker of subclinical myocardial injury (9, 10). It has been suggested that the association of hs-cTnT with cardiac outcomes is mediated by non-atherosclerotic mechanisms (7, 8, 11, 12). Although left ventricular mass is independently associated with detectable levels of hs-cTnT, coronary artery calcium (a marker of coronary atherosclerosis) is not independently associated with detectable levels of hs-cTnT (8, 9) and the association of hs-cTnT was stronger for total mortality and heart failure than for CHD (7, 9). It has been hypothesized that hs-cTnT may be a marker of subclinical small vessel disease rather than atherosclerosis (13).

There is some evidence that cognitive function and dementia are associated with subclinical cardiovascular disease as assessed by carotid intima medial thickness (14). Hs-cTnT has been investigated or proposed to be investigated using the ARIC cohort in terms of its relationship to stroke-related mortality (HR: 3.3, 95% CI: 1.3, 8.7) (MSP #1811), in terms of its relationship to incident stroke (MSP #1899), and in terms of its relationship to small vessel disease in the brain (MSP #1856). It has been hypothesized that the same persons with subclinical myocardial injury may also have subclinical small vessel disease in the brain. The subclinical small vessel disease in the brain may manifest as subtle impairment on standardized cognitive tests and may place the person at higher risk for dementia later in life. Alternatively, subclinical myocardial injury may directly lead to cerebral injury, thereby causing impairments on cognitive function tests and increasing risk for dementia. To our knowledge, no previous studies have examined the possible association of cardiac troponin measured by a novel highly sensitive assay (hs-cTnT) and cognitive function and dementia.

To comprehensively characterize the relationship of hs-cTnT with cognitive function and future dementia risk in a community-based population, we propose to examine the cross-sectional association between hs-cTnT and cognitive test scores at visit 4 and to examine the prospective relationship between hs-cTnT and incident dementia hospitalization in the ARIC Study.

## 5. Main Hypothesis/Study Questions:

1. Are there cross-sectional associations between hs-cTnT and Delayed Word Recall (DWR) or Digit Symbol Substitution (DSS) or Word Fluency (WF) Test scores?

Hypothesis: Higher levels of hs-cTnT will be associated with lower cognitive test performance, independently of known risk factors.

2. Is there a prospective relationship between hs-cTnT and incident dementia hospitalization?

Hypothesis: Higher levels of hs-cTnT will be associated with incident dementia hospitalization, independently of known risk factors.

## 6. Design and analysis (study design, inclusion/exclusion, outcome and other variables of interest with specific reference to the time of their collection, summary of data analysis, and any anticipated methodologic limitations or challenges if present).

### Study Design:

Cross-sectional analysis using data from visit 4 and prospective analysis with visit 4 as baseline.

### Study Population (inclusion/exclusion criteria):

All ARIC participants who attended visit 4 and who do not meet any of the following exclusion criteria:

- CHD, CHF and stroke at or before visit 4 (this includes self-reported myocardial infarction or stroke before visit 1, or silent MI (diagnosed by electrocardiographic changes), validated MI and revascularization at or before visit 4)
- Missing hs-cTnT
- Missing any of the cognitive tests at visit 4 (DWR, DSS, WF)
- Missing covariates included in statistical models (see below)

### Exposure:

#### hs-cTnT:

hs-cTnT was measured in 2010 from stored plasma samples originally obtained from participants at visit 4 (1997-99) using a novel pre-commercially available highly sensitive assay, Elecsys Troponin T (Roche Diagnostics, Indianapolis, Indiana), on an automated Cobas e411 analyzer with a lower limit of detection (LOD) of 0.003 µg/L. Between-assay coefficients of variation were 2.6% and 6.9% for control materials with mean troponin concentrations of 2.378 µg/L and 0.029 µg/L, respectively. Measurement repeatability was assessed using blinded split samples (n=418). The reliability coefficient was 0.98 and the coefficient of variation was 15% after excluding >3 standard deviation outliers (n=3).

### Outcomes:

### 1. Cognition:

In the ARIC Study, cognitive functioning was assessed at visit 4 using three standardized tests: the DSST of the Wechsler Adult Intelligence Scale-Revised (WAIS-R) (15), the DWRT (16), and the WFT, also known as the Controlled Oral Word Association Test (COWA) of the Multilingual Aphasia Examination (17). The DSST is a test of memory, executive function and processing speed, the DWRT is a test of verbal learning and recent memory, and the WFT is a test of executive function and expressive language (15-17). Trained examiners administered the cognitive tests in a standardized order during one session in a quiet room. Examiner performance was monitored by audio tape recording. Recordings were reviewed locally and shared across centers to ensure consistency with testing procedures.

### 2. Incident Dementia Hospitalization:

The ARIC Study obtains hospitalization information from annual telephone contact with study participants and through active surveillance of all hospitalizations in the study communities. We will define time to first hospitalization with an ICD-9 code for dementia using the following ICD-9 codes (listed anywhere in the hospital discharge record): Alzheimer's disease (331.0), vascular dementia (290.4) or dementia of other etiology, including senile, presenile, and frontotemporal dementias, and dementias secondary to a general medical condition (e.g. Parkinson's disease) (290.0, 290.1, 290.2, 290.3, 290.9, 294.1, 294.2, 294.8, 294.9, 331.1, 331.2, 331.8, 331.9) (18). We will use incident dementia hospitalization data through 2009 (or most recent data available). We have previously reported age- and race-specific rates of hospitalization with dementia (18).

### Covariates:

Age, sex, race/field center, body mass index, income, diabetes, education, total cholesterol, HDL cholesterol, systolic and diastolic blood pressure, blood pressure medication use, apoE genotype, smoking, alcohol consumption, physical activity. All covariates listed are from visit 4, except for education level, which is only assessed at visit 1.

### Potential effect modifiers:

We will formally test for interaction by age, race, and sex. We will perform stratified analysis if we observe evidence for significant effect modification.

### Statistical Analysis:

We will analyze hs-cTnT both continuously and categorically. For the categorical analysis, the 33.5% of the ARIC population with undetectable levels ( $<0.003 \mu\text{g/L}$ ) will be the reference group (group 1). The remaining 66.5% of the ARIC population will be split in to approximate thirds: cTnT 0.003 to 0.005  $\mu\text{g/L}$  (group 2), 0.006 to 0.008  $\mu\text{g/L}$  (group 3), and higher levels will be divided at approximately the 90<sup>th</sup> percentile of the ARIC population (group 4: 0.09 to 0.013  $\mu\text{g/L}$ ; group 5:  $\geq 0.014 \mu\text{g/L}$ ). We will also analyze hs-cTnT using two different binary variables: detectable ( $<0.003 \mu\text{g/L}$ ) versus

non-detectable ( $\geq 0.003 \mu\text{g/L}$ ) and elevated ( $>99^{\text{th}}$  percentile from a healthy population ages 20-70 years [Roche Diagnostics, Indianapolis, Indiana]) ( $>0.014 \mu\text{g/L}$ ) versus non-elevated ( $\leq 0.014 \mu\text{g/L}$ ). For the continuous analysis, we will assign undetectable levels of hs-cTnT a value of  $0.0015 \mu\text{g/L}$  (half the lower LOD). These methods have been described previously (7, 9).

We will use linear and logistic regression models to assess the cross-sectional association between hs-cTnT and cognitive test scores (DWR, DSS, WF) (Visit 4). Logistic regression models will be used to estimate odds ratios (95% confidence intervals) for the performing in the bottom quintile on each cognitive test by detectable hs-cTnT (vs non-detectable) and by elevated hs-cTnT (versus not elevated hs-cTnT) category.

We will use Cox proportional hazard models to assess the prospective association between hs-cTnT and incident dementia hospitalization.

We will also model the association of hs-cTnT with cognitive function and incident dementia using piece-wise linear splines (knots at as defined above) and using restricted cubic splines. We will perform the spline analyses both among those with detectable levels only and using the entire population where we will assign undetectable levels of hs-cTnT a value of  $0.0015 \mu\text{g/L}$  (half the lower LOD).

We will perform three statistical models:

- Model 1: adjust for demographic factors (age, gender, race/field center, education, income)
- Model 2: Model 1 + behavioral factors (physical activity, alcohol consumption, smoking)
- Model 3: Model 2 + genetic and cardiovascular risk factors (apoE, total cholesterol, HDL cholesterol, systolic and diastolic blood pressure, blood pressure medication use)

We will perform sensitivity analyses using visit 2 cognitive test data to assess the association of hs-cTnT at visit 4 with the past trajectory of cognitive function (change from visit 2 to visit 4). We can also look at the association of hs-cTnT with prospective change in cognitive function among participants who attended visit 4 and either the Brain MRI or Carotid MRI visit (2004-2006). In addition, individuals that attended the Brain MRI visit provided information on dementia, family history of dementia, and neurological function; examining the association of hs-cTnT with cognition in this subset of participants, adjusting for these additional covariates, would be useful.

#### Limitations:

A major limitation of this study will be the method of dementia ascertainment. Relying on hospital discharge data to define incident cases of dementia will likely underestimate the true incidence of dementia in the study population. However, our definition of dementia is likely to be a highly specific case definition. Additionally, because dementia hospitalization is a heterogeneous outcome, we anticipate that we will not have enough

cases to create subgroups by type of dementia (e.g. vascular, Alzheimer's). We also have only single measurements of hs-cTnT and cognitive test performance, both of which can vary over time within individuals (19, 20). Due to the cross-sectional design for examining the possible associations of hs-cTnT and cog function, we will have limited ability to draw any conclusions regarding the temporality of any observed associations. As with any observational study, we will also not be able to rule out the possibility of residual confounding.

7.a. Will the data be used for non-CVD analysis in this manuscript?  Yes  No

b. If Yes, is the author aware that the file ICTDER03 must be used to exclude persons with a value RES\_OTH = "CVD Research" for non-DNA analysis, and for DNA analysis RES\_DNA = "CVD Research" would be used?  Yes  No  
(This file ICTDER03 has been distributed to ARIC PIs, and contains the responses to consent updates related to stored sample use for research.)

8.a. Will the DNA data be used in this manuscript?  Yes  No

8.b. If yes, is the author aware that either DNA data distributed by the Coordinating Center must be used, or the file ICTDER03 must be used to exclude those with value RES\_DNA = "No use/storage DNA"?  
 Yes  No

9. The lead author of this manuscript proposal has reviewed the list of existing ARIC Study manuscript proposals and has found no overlap between this proposal and previously approved manuscript proposals either published or still in active status. ARIC Investigators have access to the publications lists under the Study Members Area of the web site at: <http://www.csc.unc.edu/ARIC/search.php>  
 Yes  No

10. What are the most related manuscript proposals in ARIC (authors are encouraged to contact lead authors of these proposals for comments on the new proposal or collaboration)?

MSP #1211: Cognitive change over 12 years and its relationship to cardiovascular risk factors: the ARIC MRI study (Knopman)

MSP #1973: Cardiovascular exposures, cognitive decline, and depression in whites and blacks (Al Hazzouri)

MSP #969: Impact of coronary artery bypass surgery on cognitive function (Knopman)

MSP #1703: Identification of candidate genes associated with cardiovascular disease that predict cognitive change in mid-life: the ARIC study (Bressler)

MSP #672: Changes in cognitive test scores in the ARIC cohort over a 6-year period (visit 2 to visit 4) and their correlation with vascular risk factors (Knopman)

MSP #1365: Midlife cardiovascular risk factors and risk of dementia hospitalization in a biracial cohort: the ARIC study (Alonso)

MSP #1856: Cardiac troponin t measured by highly sensitive assay and MRI-defined small vessel disease of the brain in the ARIC study (Dadu)

MSP #1759: Associations of traditional cardiovascular risk factors and high-sensitivity cardiac troponin T (Rubin)

MSP #1899: Troponin T, NT-proBNP, and stroke incidence (Folsom)

**11.a. Is this manuscript proposal associated with any ARIC ancillary studies or use any ancillary study data?**  Yes  No

ARIC Ancillary Study #2008.10, “Measurement of NT-proBNP and troponin T at visit 4 for the full ARIC cohort”

**11.b. If yes, is the proposal**

- A. primarily the result of an ancillary study (list number\* 2008.11)**  
 **B. primarily based on ARIC data with ancillary data playing a minor role (usually control variables; list number(s)\* \_\_\_\_\_)**

\*ancillary studies are listed by number at <http://www.csc.unc.edu/aric/forms/>

**12a. Manuscript preparation is expected to be completed in one to three years. If a manuscript is not submitted for ARIC review at the end of the 3-years from the date of the approval, the manuscript proposal will expire.**

**12b. The NIH instituted a Public Access Policy in April, 2008** which ensures that the public has access to the published results of NIH funded research. It is **your responsibility to upload manuscripts to PUBMED Central** whenever the journal does not and be in compliance with this policy. Four files about the public access policy from <http://publicaccess.nih.gov/> are posted in <http://www.csc.unc.edu/aric/index.php>, under Publications, Policies & Forms. [http://publicaccess.nih.gov/submit\\_process\\_journals.htm](http://publicaccess.nih.gov/submit_process_journals.htm) shows you which journals automatically upload articles to Pubmed central.

## References

1. Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. *Neuroepidemiology*. 2007;29(1-2):125-32. PMID: 2705925.
2. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. *Arch Neurol*. 2003;60(8):1119-22.
3. Kovacic JC, Castellano JM, Fuster V. The links between complex coronary disease, cerebrovascular disease, and degenerative brain disease. *Annals of the New York Academy of Sciences*. 2012;1254:99-105.
4. Emanuele E, Martinelli V, Abbiati V, Ricevuti G. Linking atherosclerosis to Alzheimer's disease: focus on biomarkers. *Front Biosci (Elite Ed)*. 2012;4:700-10.
5. Sahathevan R, Brodtmann A, Donnan GA. Dementia, stroke, and vascular risk factors; a review. *Int J Stroke*. 2012;7(1):61-73.
6. Tate JR. Troponin revisited 2008: assay performance. *Clin Chem Lab Med*. 2008;46(11):1489-500.
7. Saunders JT, Nambi V, de Lemos JA, Chambless LE, Virani SS, Boerwinkle E, et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart



- disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. *Circulation*. 2011;123(13):1367-76. PMID: 3072024.
8. de Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. *JAMA : the journal of the American Medical Association*. 2010;304(22):2503-12.
  9. Rubin J, Matsushita K, Ballantyne CM, Hoogeveen R, Coresh J, Selvin E. Chronic hyperglycemia and subclinical myocardial injury. *Journal of the American College of Cardiology*. 2012;59(5):484-9. PMID: 3267958.
  10. de Lemos JA, Grundy SM. Low levels of circulating troponin as an intermediate phenotype in the pathway to heart failure. *Journal of the American College of Cardiology*. 2012;59(5):490-2.
  11. Omland T, de Lemos JA, Sabatine MS, Christophi CA, Rice MM, Jablonski KA, et al. A sensitive cardiac troponin T assay in stable coronary artery disease. *The New England Journal of Medicine*. 2009;361(26):2538-47. PMID: 2997684.
  12. deFilippi CR, de Lemos JA, Christenson RH, Gottdiener JS, Kop WJ, Zhan M, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. *JAMA : the journal of the American Medical Association*. 2010;304(22):2494-502.
  13. Moreno V, Hernandez-Romero D, Vilchez JA, Garcia-Honrubia A, Cambronero F, Casas T, et al. Serum levels of high-sensitivity troponin T: a novel marker for cardiac remodeling in hypertrophic cardiomyopathy. *Journal of Cardiac Failure*. 2010;16(12):950-6.
  14. Arntzen KA, Mathiesen EB. Subclinical carotid atherosclerosis and cognitive function. *Acta Neurol Scand Suppl*. 2011(191):18-22.
  15. Wechsler D. *Wechsler Adult Intelligence Scale-Revised Manual*. 1981.
  16. Knopman DS, Ryberg S. A verbal memory test with high predictive accuracy for dementia of the Alzheimer type. *Arch Neurol*. 1989;46(2):141-5.
  17. Benton AL, Hamsher K. *Multilingual Aphasia Examination, 2nd Edition*. 1989.
  18. Alonso A, Mosley TH, Jr., Gottesman RF, Catellier D, Sharrett AR, Coresh J. Risk of dementia hospitalisation associated with cardiovascular risk factors in midlife and older age: the Atherosclerosis Risk in Communities (ARIC) study. *J Neurol Neurosurg Psychiatry*. 2009;80(11):1194-201. PMID: 2783764.
  19. Agarwal SK, Avery CL, Ballantyne CM, Catellier D, Nambi V, Saunders J, et al. Sources of variability in measurements of cardiac troponin T in a community-based sample: the atherosclerosis risk in communities study. *Clinical Chemistry*. 2011;57(6):891-7.
  20. Pavlik VN, de Moraes SA, Szklo M, Knopman DS, Mosley TH, Jr., Hyman DJ. Relation between cognitive function and mortality in middle-aged adults: the atherosclerosis risk in communities study. *Am J Epidemiol*. 2003;157(4):327-34.